Northwell Health Named by Ethisphere As One of the World’s Most Ethical Companies

February 23, 2021

Northwell Health has been recognized as one of 2021 World’s Most Ethical Companies by the Ethisphere Institute, one of nine health systems nationwide to make the list and the only one from New York State.

Ethisphere, a global leader in defining and advancing the standards of ethical business practices, selected Northwell for the sixth time. New York’s largest health system and private employer was among 135 organizations spanning 22 countries and 47 industries to be named a Most Ethical company.

“We hold ourselves to the highest of standards and in spite of a pandemic that pushed the world to the breaking point our health care heroes continue to deliver compassionate quality care,” said Michael Dowling, president, and CEO of Northwell Health. “Our culture has carried us through this dark time, turning adversity into strength. That’s the sign of a truly ethical company and I’m proud of how we responded in New York’s time of need.”

When coronavirus disease 2019 (COVID-19) began rampaging through the region beginning in March 2020, Northwell stepped to the fore with complex medical care, expanded testing, timely clinical trials, and eventually vaccinations. Northwell has treated more than 163,000 COVID-19 patients to date, including 16,000 who were hospitalized between March and Labor Day – more than any other health system in the nation.

The criteria Ethisphere used to judge the World’s Most Ethical Companies included more than 200 questions on culture, environmental and social practices, ethics and compliance activities, governance, diversity, and initiatives to support strong cultural values. The process was streamlined and the question set expanded to gauge how applicants adapted and responded to the global health pandemic, environmental, social, and governance factors, safety, equity and inclusion, and social justice.

“We are truly honored and grateful to be counted among The World’s Most Ethical Companies,” said Greg Radinsky, senior vice president and Northwell’s chief corporate compliance officer. “Congratulations to everyone at Northwell Health for earning this recognition. This is a testament to the collective work our entire organization performs in serving our patients and communities — especially in such a trying year.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”